SecBot SecBot
SECBOTREPLAY Home › Report › ACAD

ACAD · Multiple C-suite executives at Acadia Pharmaceuticals, including the…

ACADIA PHARMACEUTICALS INC · CLUSTER filed Mar 24, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 4/10

CLUSTER filed Mar 24, 2026 at 20:00 ET

Multiple C-suite executives at Acadia Pharmaceuticals, including the CEO, CFO, and other senior officers, conducted open-market share sales totaling approximately $504,000 over a two-day period, concurrent with the exercise of stock options. The sales represent a coordinated liquidity event following derivative exercises, but the dollar amount is small relative to the company's $3.8B market cap.

  • CEO Catherine Owen Adams sold $249,932 worth of shares, CFO Mark Schneyer sold $158,332, and other C-suite executives sold an additional $95,766 in open-market transactions.
  • All sales were preceded by or concurrent with the exercise of stock options (M-coded transactions), indicating pre-planned option monetization rather than discretionary selling of held shares.
  • Total open-market sale value across all insiders: ~$504,000 over two days.
  • Total value represents only 0.013% of Acadia's $3.8B market cap, well below the 0.1% threshold for materiality.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access